Literature DB >> 10839924

Volatile anesthetics activate the human tandem pore domain baseline K+ channel KCNK5.

A T Gray1, B B Zhao, C H Kindler, B D Winegar, M J Mazurek, J Xu, R A Chavez, J R Forsayeth, C S Yost.   

Abstract

BACKGROUND: Previous studies have identified a volatile anesthetic-induced increase in baseline potassium permeability and concomitant neuronal inhibition. The emerging family of tandem pore domain potassium channels seems to function as baseline potassium channels in vivo. Therefore, we studied the effects of clinically used volatile anesthetics on a recently described member of this family.
METHODS: A cDNA clone containing the coding sequence of KCNK5 was isolated from a human brain library. Expression of KCNK5 in the central nervous system was determined by Northern blot analysis and reverse-transcription polymerase chain reaction. Functional expression of the channel was achieved by injection of cRNA into Xenopus laevis oocytes.
RESULTS: Expression of KCNK5 was detected in cerebral cortex, medulla, and spinal cord. When heterologously expressed in Xenopus oocytes, KCNK5 currents exhibited delayed activation, outward rectification, proton sensitivity, and modulation by protein kinase C. Clinical concentrations of volatile general anesthetics potentiated KCNK5 currents by 8-30%.
CONCLUSION: Human KCNK5 is a tandem pore domain potassium channel exhibiting delayed activation and sensitivity to volatile anesthetics and may therefore have a role in suppressing cellular excitability during general anesthesia.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10839924     DOI: 10.1097/00000542-200006000-00032

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  24 in total

1.  Serotonergic raphe neurons express TASK channel transcripts and a TASK-like pH- and halothane-sensitive K+ conductance.

Authors:  Christopher P Washburn; Jay E Sirois; Edmund M Talley; Patrice G Guyenet; Douglas A Bayliss
Journal:  J Neurosci       Date:  2002-02-15       Impact factor: 6.167

2.  The TASK-1 two-pore domain K+ channel is a molecular substrate for neuronal effects of inhalation anesthetics.

Authors:  J E Sirois; Q Lei; E M Talley; C Lynch; D A Bayliss
Journal:  J Neurosci       Date:  2000-09-01       Impact factor: 6.167

Review 3.  The 2P-domain K+ channels: role in apoptosis and tumorigenesis.

Authors:  Amanda J Patel; Michel Lazdunski
Journal:  Pflugers Arch       Date:  2004-05-05       Impact factor: 3.657

4.  TASK-like K+ channels mediate effects of 5-HT and extracellular pH in rat dorsal vagal neurones in vitro.

Authors:  Sarah E Hopwood; Stefan Trapp
Journal:  J Physiol       Date:  2005-07-14       Impact factor: 5.182

5.  Kinetics of anesthetic-induced conformational transitions in a four-alpha-helix bundle protein.

Authors:  Ken Solt; Jonas S Johansson; Douglas E Raines
Journal:  Biochemistry       Date:  2006-02-07       Impact factor: 3.162

Review 6.  Sodium channels and the synaptic mechanisms of inhaled anaesthetics.

Authors:  H C Hemmings
Journal:  Br J Anaesth       Date:  2009-06-09       Impact factor: 9.166

Review 7.  Anaesthetic mechanisms: update on the challenge of unravelling the mystery of anaesthesia.

Authors:  Andrea Kopp Lugli; Charles Spencer Yost; Christoph H Kindler
Journal:  Eur J Anaesthesiol       Date:  2009-10       Impact factor: 4.330

8.  Discrete change in volatile anesthetic sensitivity in mice with inactivated tandem pore potassium ion channel TRESK.

Authors:  Yun Jeong Chae; Jianan Zhang; Paul Au; Marta Sabbadini; Guo-Xi Xie; C Spencer Yost
Journal:  Anesthesiology       Date:  2010-12       Impact factor: 7.892

Review 9.  General anesthesia mediated by effects on ion channels.

Authors:  Cheng Zhou; Jin Liu; Xiang-Dong Chen
Journal:  World J Crit Care Med       Date:  2012-06-04

10.  The effect of different anesthetics on tumor cytotoxicity by natural killer cells.

Authors:  Kazumasa Tazawa; Sophia Koutsogiannaki; Matthew Chamberlain; Koichi Yuki
Journal:  Toxicol Lett       Date:  2016-12-08       Impact factor: 4.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.